TrialsgrambetaRCTs are beautiful

EXPLORER-HCM

2020

Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

In 251 patients with symptomatic obstructive HCM (NYHA II-III, LVOT gradient ≥50 mmHg), mavacamten improved the composite of peak VO2 and NYHA functional class compared with placebo.

Result

Composite responder (peak VO2 rise plus NYHA-class improvement) at week 30
Absolute difference
20 points
NNT
5
Effect estimate

difference19.495% CI 8.7-30.1 · P = 0.0005

Absolute difference and NNT are derived from the event rates.

Also reported: LVOT gradient and symptoms also improved.

Original publication
Subtopic
myosin inhibitor
Design
Double-blind placebo-controlled RCT, phase 3
Relevance
Important: one of several pillars.
Source
Olivotto I, et al. Lancet. 2020;396(10253):759-769.doi 10.1016/S0140-6736(20)31792-X

Discussion & critique

Surrogate/functional composite endpoint rather than hard outcomes, with a modest absolute responder difference. First pivotal trial of a cardiac myosin inhibitor, leading to FDA approval of mavacamten for obstructive HCM.

Discussed in podcasts